Navigation Links
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Date:8/19/2007

WESTMINSTER, Colo., Aug. 15 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the initiation of patient enrollment in a Phase 1, open-label, multi-center study of the Company's novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

"Based on our experience with PDX in patients with peripheral T-cell lymphoma, we're excited to initiate this study in patients with cutaneous T- cell lymphoma and view this effort as a natural progression of our PDX development program in hematologic malignancies," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "Therapies currently used to treat cutaneous T-cell lymphoma fail to produce durable remissions in the majority of patients with advanced disease."

In this study, patients with either relapsed or refractory cutaneous T- cell lymphoma will receive PDX as part of a weekly schedule for two or three weeks followed by one week of rest. Patients will receive starting doses of PDX at 30 mg/m2, with dose reduction in subsequent cohorts based on toxicity. Up to 56 evaluable patients will be enrolled in the study with the objective of determining the optimal dose and safety profile of PDX in this population. A total of 20 of these patients will be enrolled at what is determined to be the optimal dose and schedule. Steven Horwitz, M.D., Assistant Attending Physician, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, will serve as the study chair.

"Given the evidence of activity observed to date with PDX in patients with aggressive T-cell lymphomas, coupled with the common cell lineage between PTCL and CTCL, there is a str
'/>"/>

SOURCE Allos Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 TWi Pharmaceuticals, Inc. ... TWi Pharmaceuticals USA , has obtained ... United States.  It has been in close contact with ... expects to have its own label specialty generic products ... the U.S. pharma market. According to IMS ...
(Date:4/16/2015)... , April 16, 2015 A drug commonly taken ... of people with multiple sclerosis (MS), according to a study ... of Neurology,s 67th Annual Meeting in Washington, DC ... "About half of people with MS experience at some point ... which the nerve carrying vision from the eye to the ...
(Date:4/16/2015)... , April 16, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Tuesday, April 21, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
Breaking Medicine Technology:Epilepsy Drug May Preserve Eyesight for People with MS 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been undergoing ... to run maintenance on our shipping facilities to update ... PR Director. "It disrupted our regular shipping schedule but ... on track after having completed the maintenance." , Now, ... which has not allowed some calls to come in ...
(Date:4/18/2015)... April 18, 2015 ā€œ ArcAngel ā€ was ... takes a look at the latest and coolest ... Troohey, the host of AppWatch and technology expert, conducted the ... personal safety app. , In a turbulent world, people ... Calling 911 should always be their first move, but some ...
(Date:4/17/2015)... 17, 2015 John Evans, a Gardant ... the Patio from 2 p.m. to 3 p.m. on ... 1320 Executive Ct. in Pekin, Illinois, serves older adults ... some help to maintain their independence. , Becky Baker ... treats will be served during the luau. , For ...
(Date:4/17/2015)... Oklahoma (PRWEB) April 17, 2015 Alcohol ... Drug Dependence (NCADD) notes that drinking and driving has ... At the same time, the link between alcohol ... as domestic abuse and violence and sexual assault, and ... According to the NCADD, 5.3 million adults in America ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive ... Wednesday April 15th, the European Parliament joined its voice ... the Armenian Genocide, ā€œpaying tribute, on the eve of ... innocent Armenian victims who perished in the Ottoman Empire.ā€ ... for this timely and needed recognition of a tragic ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Temporary Number Available 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3
... taken ill Wednesday after inhaling methane gas leaking from a colliery ... leak was reported early morning from the Bathdih colliery of Bharat ... ,The 10 people of Barari Basti area who fell ... to be in critical condition. ,BCCL officials have rushed ...
... the ghastly video.,A slender girl dragged along by her headlocks, on ... a torrent, then her head is smashed with a concrete ... then victorious shouts are heard. ,In the eyes ... Duaa Khalil Aswad, 17, was to love a boy from another ...
... Administration (FDA) has approved the first birth control pill ... monthly preparation of pregnancy. ,Lybrel, produced ... a low dosage of hormones ethinyl estradiol and levonorgestrel, ... pill prevents conception by halting menstrual period indefinitely. ...
... at the Albert Einstein College of Medicine in Yeshiva ... ability to use radioactivity as an energy source ... ,According to Dr. Arturo Casadevall, chair of microbiology and ... this finding could trigger a recalculation of the Earth's ...
... Sipping tea is far better than drinking water, researchers said. ... three or more cups of tea can reduce the risk ... Carrie Ruxton from King's College London, it is a wrong ... better than water as it contains antioxidants. It does not ...
... of the state-run super speciality SSKM Hospital in Kolkata was ... during a medical test Tuesday night. ,"We ... charges of outraging the modesty of this 32-year-old lady during ... told IANS. ,"A complaint was lodged by the ...
Cached Medicine News:Health News:Women in Iraq More Unsafe Than Ever 2Health News:Astronauts can Now Feed on 'radiation-eating' Fungi 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: